Advancing Chemotype Agnostic Platform Methods for ADC Release & Characterization
- Navigate the increasing complexity of novel ADC modalities and chemotypes to accelerate development timelines and reduce costs across a growing portfolio of assets
- Establish a suite of robust, chemotype-agnostic platform methods for critical quality attributes, to minimize the number of methods requiring development, validation, and transfer, achieving greater efficiency, speed, and consistency across ADC development
- Implement a holistic, platform-based analytical strategy to de-risk project timelines, simplify tech transfer to QC, and create a more scalable, cost-effective framework for the future of ADC development